Literature DB >> 20383591

Plasma protein binding of luciferase substrates influences sensitivity and accuracy of bioluminescence imaging.

Marleen Keyaerts1, Carola Heneweer, Lea O Tchouate Gainkam, Vicky Caveliers, Bradley J Beattie, Geert A Martens, Christian Vanhove, Axel Bossuyt, Ronald G Blasberg, Tony Lahoutte.   

Abstract

INTRODUCTION: Potential confounding factors in bioluminescence imaging (BLI)-quantification need to be identified to improve its accuracy and repeatability.
PURPOSE: The aim of this study was to study the degree to which plasma protein binding of BLI substrates influences signal intensity and quantification, both in vitro and in vivo. PROCEDURES: Protein binding was assessed using ultrafiltration and spectrophotometry. Effects of increasing serum protein concentrations were studied in vitro, in intact cells expressing Firefly or Renilla luciferase, and in vivo, in a doxorubicin-induced hypoalbuminemia mouse model.
RESULTS: Increasing concentrations of serum proteins showed an important negative effect on BLI signal intensity, both for D-luciferin and coelenterazine-dependent reactions. This was due to a decrease in the free fraction of the substrate in the presence of serum proteins of up to 88%. In vivo, hypoalbuminemia was associated with higher BLI signal intensity, although this was only significant in animals with a major decrease in albumin (<2 g/dL). Important kinetic differences, including earlier peak luminescence and a more rapid decline in luminescence, were observed for coelenterazine-dependent BLI under hypoalbuminemic conditions. Changes in protein concentrations can significantly influence BLI quantification and its presence decreases sensitivity in vitro. In vivo, effects on signal intensity and kinetics are only noted at severe hypoalbuminemia and can be neglected in most experimental designs. These findings again emphasize the need for careful interpretation of BLI quantification data.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20383591     DOI: 10.1007/s11307-010-0325-x

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  19 in total

Review 1.  Molecular imaging.

Authors:  R Weissleder; U Mahmood
Journal:  Radiology       Date:  2001-05       Impact factor: 11.105

Review 2.  Optical imaging: current applications and future directions.

Authors:  Gary D Luker; Kathryn E Luker
Journal:  J Nucl Med       Date:  2007-12-12       Impact factor: 10.057

3.  Kinetics of product inhibition during firefly luciferase luminescence.

Authors:  J J Lemasters; C R Hackenbrock
Journal:  Biochemistry       Date:  1977-02-08       Impact factor: 3.162

4.  Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging.

Authors:  A Rehemtulla; L D Stegman; S J Cardozo; S Gupta; D E Hall; C H Contag; B D Ross
Journal:  Neoplasia       Date:  2000 Nov-Dec       Impact factor: 5.715

Review 5.  Inducible rodent models of acquired podocyte diseases.

Authors:  Jeffrey W Pippin; Paul T Brinkkoetter; Fionnualla C Cormack-Aboud; Raghu V Durvasula; Peter V Hauser; Jolanta Kowalewska; Ronald D Krofft; Christine M Logar; Caroline B Marshall; Takamoto Ohse; Stuart J Shankland
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-10

6.  A specific mechanism for nonspecific activation in reporter-gene assays.

Authors:  Douglas S Auld; Natasha Thorne; Dac-Trung Nguyen; James Inglese
Journal:  ACS Chem Biol       Date:  2008-07-01       Impact factor: 5.100

7.  In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma.

Authors:  Paxton V Dickson; Blair Hamner; Catherine Y C Ng; Marshall M Hall; Junfang Zhou; Phillip W Hargrove; M Beth McCarville; Andrew M Davidoff
Journal:  J Pediatr Surg       Date:  2007-07       Impact factor: 2.545

8.  ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging.

Authors:  Yimao Zhang; Joseph P Bressler; Jeff Neal; Bachchu Lal; Hyo-Eun C Bhang; John Laterra; Martin G Pomper
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

9.  Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden.

Authors:  Zain Paroo; Robert A Bollinger; Dwaine A Braasch; Edmond Richer; David R Corey; Peter P Antich; Ralph P Mason
Journal:  Mol Imaging       Date:  2004-04       Impact factor: 4.488

10.  How reproducible is bioluminescent imaging of tumor cell growth? Single time point versus the dynamic measurement approach.

Authors:  Shingo Baba; Steve Y Cho; Zhaohui Ye; Linzhao Cheng; James M Engles; Richard L Wahl
Journal:  Mol Imaging       Date:  2007 Sep-Oct       Impact factor: 3.250

View more
  7 in total

1.  Multimodal imaging of stem cell implantation in the central nervous system of mice.

Authors:  Nathalie De Vocht; Kristien Reekmans; Irene Bergwerf; Jelle Praet; Chloé Hoornaert; Debbie Le Blon; Jasmijn Daans; Zwi Berneman; Annemie Van der Linden; Peter Ponsaerts
Journal:  J Vis Exp       Date:  2012-06-13       Impact factor: 1.355

2.  Bioluminescence imaging of therapy response does not correlate with FDG-PET response in a mouse model of Burkitt lymphoma.

Authors:  Marijke De Saint-Hubert; Ellen Devos; Abdelilah Ibrahimi; Zeger Debyser; Luc Mortelmans; Felix M Mottaghy
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-07-10

Review 3.  Seeing stem cells at work in vivo.

Authors:  Amit K Srivastava; Jeff W M Bulte
Journal:  Stem Cell Rev Rep       Date:  2014-02       Impact factor: 5.739

4.  Dual systemic tumor targeting with ligand-directed phage and Grp78 promoter induces tumor regression.

Authors:  Azadeh Kia; Justyna M Przystal; Nastasia Nianiaris; Nicholas D Mazarakis; Paul J Mintz; Amin Hajitou
Journal:  Mol Cancer Ther       Date:  2012-10-10       Impact factor: 6.261

5.  Inhibition of firefly luciferase by general anesthetics: effect on in vitro and in vivo bioluminescence imaging.

Authors:  Marleen Keyaerts; Isabel Remory; Vicky Caveliers; Karine Breckpot; Tomas J Bos; Jan Poelaert; Axel Bossuyt; Tony Lahoutte
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

6.  LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomib.

Authors:  Krzysztof M Mrozik; Chee M Cheong; Duncan R Hewett; Jacqueline E Noll; Khatora S Opperman; Alaknanda Adwal; Darryl L Russell; Orest W Blaschuk; Kate Vandyke; Andrew C W Zannettino
Journal:  FASEB Bioadv       Date:  2020-06-15

7.  In vivo bioluminescence imaging of vascular remodeling after stroke.

Authors:  Joanna M Adamczak; Gabriele Schneider; Melanie Nelles; Ivo Que; Ernst Suidgeest; Louise van der Weerd; Clemens Löwik; Mathias Hoehn
Journal:  Front Cell Neurosci       Date:  2014-09-05       Impact factor: 5.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.